Journal Basic Info
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.Major Scope
- Thoracic Oncology
- Surgical Oncology
- Chemotherapy and Radiotherapy
- Stomach Cancer
- Radiation Therapy
- Paediatric Cancers
- Endoscopy Methods
- Ovarian Cancer
Abstract
Citation: Clin Oncol. 2019;4(1):1676.DOI: 10.25107/2474-1663.1676
Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Non-Small Cell Lung Cancer (NSCLC), Practical Pharmacological Aspects
Alexandru C Grigorescu and Teodorescu Laura Mihaela
Department of Medical Oncology, The Oncological Institute of Bucharest, Romania
V Babes Diagnostic and Treatment Center, Romania
*Correspondance to: Alexandru C Grigorescu
PDF Full Text Case Report | Open Access
Abstract:
Tyrosine Kinase Inhibitors are new drugs developed in the last decade. For Non-Small Cell Lung Cancer this drug brought more hope for patients with this disease. Also TKIs are better tolerated then chemotherapy. The efficacy of TKIs is dependent of the presence of Epidermal Grows Factor Receptor gene mutation. This mutation account for about 9% of patients with lung cancer in Europe. This short review try to give the minimal knowledge to clinicians, especially medical oncologists, about mechanism of action, pharmacokinetics of TKIs used in the treatment NSCLC.
Keywords:
Tyrosine Kinase Inhibitors (TKI); Non-small cell lung cancer; Pharmacokinetics aspects
Cite the Article:
Grigorescu AC, Mihaela TL. Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Non-Small Cell Lung Cancer (NSCLC), Practical Pharmacological Aspects. Clin Oncol. 2019;4:1676.